Lyell Immunopharma, Inc.

LYEL · Nasdaq · United States

Share price · LYEL

$13.89-1.90 (-12.03%) 3M

close as of 2026-11-18 · 24h delayed · vol 116K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LYEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+43.3%
  2. 18 Aug 2026+16.5%

    Nothing announced by LYEL that day or the session before.

  3. 7 Jul 2026+13.3%

    Nothing announced by LYEL that day or the session before.

  4. 30 Jun 2026+10.2%
  5. 26 Jun 2026-7.0%

    Nothing announced by LYEL that day or the session before.

  6. 22 Jun 2026-6.0%

    Nothing announced by LYEL that day or the session before.

  7. 3 Jun 2026-15.6%

    Nothing announced by LYEL that day or the session before.

  8. 2 Jun 2026-13.2%

    Nothing announced by LYEL that day or the session before.

  9. 14 Apr 2026-5.8%

    Nothing announced by LYEL that day or the session before.

  10. 13 Apr 2026+10.8%

    Nothing announced by LYEL that day or the session before.

Share of unusual movement by asset

For each asset, the share of LYEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
LYL273
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—80%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
CD19 / CD20Cell therapy
Non-Hodgkin Lymphoma
Large B-Cell Lymphoma
Phase 1/2
GCC (guanylyl cyclase C, GUCY2C)Cell therapy
Colorectal Cancer
Metastatic Colorectal Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
June 2028 (1)
LYL273Phase 1/2Colorectal Cancer
Est. primary completion 2028-06 · NCT05319314 · CT.gov ↗
What to watch
December 2028 (1)
Rondecabtagene autoleucelPhase 1/2Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Est. primary completion 2028-12-31 · NCT05826535 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Rondecabtagene autoleucelPhase 3Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma …
Est. primary completion 2029-12 · NCT07188558 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$41M$94M+ $85M short-term inv.$46M-$35M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$40M$75M+ $131M short-term inv.$45M-$34M operating cash flowreport ↗
2026-Q1$0$37M$92M+ $163M short-term inv.$24M-$39M operating cash flowreport ↗
2025-Q3<$0.1M$28M$125M+ $196M short-term inv.$39M-$29M operating cash flowreport ↗
2025-Q2<$0.1M$35M$100M+ $178M short-term inv.$43M-$34M operating cash flowreport ↗
2025-Q1<$0.1M$43M$122M+ $181M short-term inv.$52M-$55M operating cash flowreport ↗
2024-Q3<$0.1M$40M$101M+ $340M short-term inv.$45M-$35M operating cash flowreport ↗
2024-Q2<$0.1M$40M$134M+ $358M short-term inv.$46M-$38M operating cash flowreport ↗
2024-Q1$0$43M$126M+ $401M short-term inv.$61M-$42M operating cash flowreport ↗
2023-Q3<$0.1M$44M$287M+ $289M short-term inv.$51M-$38M operating cash flowreport ↗
2023-Q2<$0.1M$47M$225M+ $371M short-term inv.$64M-$39M operating cash flowreport ↗
2023-Q1$0.1M$45M$110M+ $503M short-term inv.$67M-$46M operating cash flowreport ↗
2022-Q3$0$42M$117M+ $532M short-term inv.$70M-$37M operating cash flowreport ↗
2022-Q2$36M$44M$206M+ $450M short-term inv.$36M-$44M operating cash flowreport ↗
2022-Q1$0.6M$36M$223M+ $391M short-term inv.$68M-$48M operating cash flowreport ↗
2021-Q3$2.8M$31M$394M+ $225M short-term inv.$49M-$26M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M—$62M+ $187M short-term inv.$69M-$150M operating cash flowreport ↗

Lyell Immunopharma reported revenue of $0.04M for fiscal year 2025, down 33.3% YoY from $0.06M. R&D spend was not disclosed, cash and equivalents were $61.77M, and the company reported a net loss of $274.45M, with quarterly net burn of $274.45M.

The company is advancing ronde-cel, a dual-targeting CD19/CD20 CAR T-cell candidate, in the pivotal PiNACLE trial for third-line-or-later large B-cell lymphoma and the Phase 3 PiNACLE-H2H trial in the second-line setting, with patient dosing having commenced in February 2026. In November 2025, Lyell acquired an exclusive global license for LYL273, a GCC-targeted CAR T-cell candidate for metastatic colorectal cancer, from Innovative Cellular Therapeutics, and updated clinical data for ronde-cel were presented at the December 2025 ASH annual meeting.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.1M—$107M+ $265M short-term inv.$86M-$162M operating cash flowreport ↗
2023-FY$0.1M$183M$146M+ $401M short-term inv.$59M-$164M operating cash flowreport ↗
2022-FY$85M$159M$124M+ $517M short-term inv.$46M-$170M operating cash flowreport ↗
2021-FY$11M$139M$294M+ $321M short-term inv.$63M-$126M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 4 purchases ($75.0M), 29 sales ($613K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Bulis Veronica Sanchez · VP, Corporate ControllerOpen-market sale416$15.93$7KForm 4
2026-11-10Seely Lynn · director, President and CEOOpen-market sale545$15.93$9KForm 4
2026-11-10Hill Stephen J. · Chief Operating OfficerOpen-market sale88$15.93$1KForm 4
2026-11-10Lee Gary K. · Chief Scientific OfficerOpen-market sale129$15.93$2KForm 4
2026-11-04ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT; Burow Kristina; BERNS PAUL L; BYBEE CLINTON · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase2,321,262$10.77$25.0MForm 4
2026-11-04ARCH Venture Partners IX, LLC; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners IX Overage, L.P. · 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase2,321,262$10.77$25.0MForm 4
2026-10-12Aguirre Jarrad Mattieu · Chief Medical OfficerOpen-market sale422$8.63$4KForm 4
2026-09-10Shook David · Chief Medical OfficerOpen-market sale500$12.70$6KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 73 reporting institutions held 12.0M shares ($237.0M, 48.7% of shares outstanding).

#InstitutionSharesValue
1ARCH Venture Management, LLC3,247,162$65.1M
2GSK plc1,512,659$30.3M
3Foresite Capital Management IV, LLC800,399$16.1M
4Orland Properties Ltd754,698$15.1M
5VANGUARD CAPITAL MANAGEMENT LLC718,155$14.4M
6Almitas Capital LLC577,807$11.6M
7Foresite Capital Management V, LLC477,078$9.6M
8MILLENNIUM MANAGEMENT LLC458,905$9.2M
9CITADEL ADVISORS LLC381,462$7.7M
10venBio Partners LLC337,697$6.8M
11SUSQUEHANNA INTERNATIONAL GROUP, LLP310,198$6.2M
12Alphabet Inc.293,256$5.9M
13BlackRock, Inc.191,820$3.8M
14GEODE CAPITAL MANAGEMENT, LLC166,980$3.4M
15MARSHALL WACE, LLP148,516$3.0M